Studies
Study Overview
- Astra-Zeneca D5660C-00004: PD-L1-AK + Stat3-ASO / + CXCR2 Inhibitor in HNSCC, EudraCT No.: 2015-002525-19
- Merck EMR 200647-001: PD-L1-AK – TGFbeta ligand trap, metastatic or locally advanced solid tumors and expansion to selected indications, EudraCT 2015-004366-28
Kommentarbereich geschlossen.